PSTV Net Loss Widens to $16.7M Amid R&D Cuts, Cash Boosted by Equity Raises

TL;DR

**PSTV is burning cash fast, but recent equity raises have bought them more runway; still a high-risk bet on future drug success.**

AI Summary

PLUS THERAPEUTICS, INC. (PSTV) reported a net loss of $4.423 million for the three months ended September 30, 2025, an increase from a net loss of $2.874 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss significantly widened to $16.673 million from $9.075 million in the prior year. Grant revenue decreased to $1.397 million for the three months ended September 30, 2025, down from $1.456 million in 2024, and for the nine months, it fell to $3.846 million from $4.412 million. Operating expenses for the nine months decreased to $13.402 million in 2025 from $15.207 million in 2024, primarily due to a reduction in research and development expenses from $8.394 million to $5.438 million. The company's cash and cash equivalents dramatically increased to $13.289 million as of September 30, 2025, from $76 thousand at December 31, 2024, largely driven by $27.508 million in net cash provided by financing activities, including $19.612 million from the sale of common stock under the Lincoln Park Purchase Agreement. Total stockholders' equity shifted from a deficit of $8.949 million at December 31, 2024, to a positive $5.054 million at September 30, 2025, reflecting significant capital raises. The company continues to focus on developing treatments for cancer and other life-threatening diseases, with its CNSide Diagnostics subsidiary developing the CNSide Test.

Why It Matters

For investors, PSTV's substantial increase in cash and shift to positive stockholders' equity, driven by significant equity raises, indicates a strengthened financial position to fund ongoing clinical trials and operations. However, the widening net loss and declining grant revenue highlight the continued burn rate and reliance on external financing, which could dilute existing shareholders. The reduction in R&D spending might impact the pace of drug development, a critical factor for a clinical-stage pharmaceutical company. Competitively, the ability to sustain R&D is crucial for PSTV to advance its cancer treatments and the CNSide Test against larger, better-funded biopharmaceutical firms, directly affecting its long-term market viability and potential for employees and customers.

Risk Assessment

Risk Level: high — The company reported a net loss of $16.673 million for the nine months ended September 30, 2025, significantly higher than the $9.075 million loss in the prior year, indicating a substantial cash burn. While cash and cash equivalents increased to $13.289 million, this was primarily due to $27.508 million in financing activities, including common stock sales, which can lead to significant shareholder dilution.

Analyst Insight

Investors should closely monitor PSTV's progress in clinical trials and regulatory approvals for its product candidates, as the company's valuation is heavily dependent on these milestones. Given the high reliance on equity financing and widening losses, new investors should exercise extreme caution and existing shareholders should be aware of potential further dilution.

Financial Highlights

debt To Equity

N/A

revenue

$1.397M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$4.423M

eps

N/A

gross Margin

N/A

cash Position

$13.289M

revenue Growth

-3.9%

Revenue Breakdown

Key Numbers

• $16.673M — Net Loss (Widened from $9.075M in 9M 2024, indicating increased burn rate.)
• $13.289M — Cash and Cash Equivalents (Significant increase from $76K at Dec 31, 2024, due to financing activities.)
• $5.054M — Total Stockholders' Equity (Shifted from a $8.949M deficit at Dec 31, 2024, reflecting capital raises.)
• $5.438M — Research and Development Expenses (Decreased from $8.394M in 9M 2024, potentially impacting drug development pace.)
• $19.612M — Proceeds from Lincoln Park Purchase Agreement (Major contributor to cash increase, but also source of dilution.)
• 131,863,969 — Common Shares Outstanding (Increased from 6,154,758 at Dec 31, 2024, indicating significant dilution.)

Key Players & Entities

• PLUS THERAPEUTICS, INC. (company) — Registrant
• CNSide Diagnostics, LLC (company) — Wholly owned subsidiary developing CNSide Test
• Lincoln Park Purchase Agreement (company) — Source of $19.612 million in common stock proceeds
• Nasdaq Capital Market (regulator) — Exchange where PSTV Common Stock is registered
• $13,289 (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $16,673 (dollar_amount) — Net loss for the nine months ended September 30, 2025
• $5,438 (dollar_amount) — Research and development expenses for the nine months ended September 30, 2025
• $27,508 (dollar_amount) — Net cash provided by financing activities for the nine months ended September 30, 2025
• 137,429,055 (dollar_amount) — Shares of common stock outstanding as of October 29, 2025

FAQ

Risk Factors

• Continued Net Losses and Burn Rate [high — financial]: The company reported a net loss of $4.423 million for Q3 2025, an increase from $2.874 million in Q3 2024. For the nine months ended September 30, 2025, the net loss widened to $16.673 million from $9.075 million in the prior year. This escalating burn rate necessitates ongoing capital infusions to sustain operations.
• Dilution from Equity Financing [high — financial]: The significant increase in cash position, from $76 thousand to $13.289 million, was primarily driven by $27.508 million in financing activities, including $19.612 million from the sale of common stock under the Lincoln Park Purchase Agreement. This resulted in a substantial increase in common shares outstanding from 6,154,758 at December 31, 2024, to 131,863,969 as of September 30, 2025, indicating significant dilution for existing shareholders.
• Dependence on Grant Revenue [medium — operational]: Grant revenue decreased to $1.397 million for Q3 2025 from $1.456 million in Q3 2024, and for the nine months, it fell to $3.846 million from $4.412 million. This decline highlights a potential over-reliance on non-core revenue streams and the need to secure more sustainable product-based revenue.
• Research and Development Expense Reduction [medium — operational]: While operating expenses for the nine months decreased to $13.402 million from $15.207 million, this was primarily due to a reduction in R&D expenses from $8.394 million to $5.438 million. A sustained decrease in R&D spending could potentially slow the pace of drug development and clinical trial progress.
• Regulatory Approval Uncertainty [high — regulatory]: The company's success is contingent upon obtaining regulatory approvals from bodies like the FDA and EMA for its product candidates. Delays or failures in the approval process for its cancer treatments and the CNSide Test can significantly impact future revenue and market entry.
• Competition in Oncology and CNS Therapeutics [medium — market]: The markets for cancer and central nervous system (CNS) therapies are highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing novel treatments. PLUS THERAPEUTICS faces significant competition in bringing its product candidates to market.

Industry Context

PLUS THERAPEUTICS operates in the highly competitive biopharmaceutical sector, focusing on developing treatments for cancer and other life-threatening diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include advancements in targeted therapies, immunotherapy, and personalized medicine, alongside increasing pressure to demonstrate clinical efficacy and cost-effectiveness.

Regulatory Implications

The company's progress is heavily dependent on navigating complex regulatory pathways with agencies like the FDA and EMA. Successful development and approval of its product candidates are critical. Failure to meet regulatory standards or delays in approval processes pose significant risks to the company's ability to commercialize its therapies.

What Investors Should Do

1. Monitor R&D Spending Trends
2. Evaluate Dilution Impact
3. Track Progress on CNSide Test
4. Assess Cash Burn Rate and Future Funding Needs

Key Dates

• 2025-09-30: Quarter ended September 30, 2025 — Reported a net loss of $4.423 million and grant revenue of $1.397 million. Cash position increased significantly to $13.289 million.
• 2024-09-30: Quarter ended September 30, 2024 — Reported a net loss of $2.874 million and grant revenue of $1.456 million.
• 2025-12-31: Year ended December 31, 2024 — Company had a cash balance of $76 thousand and a total stockholders' equity deficit of $8.949 million.

Glossary

Net Loss

The total expenses incurred by a company exceed the total revenues generated over a specific period. (Indicates the company's profitability, with a widening net loss suggesting increased operational costs or decreased revenue.)

Cash and Cash Equivalents

Includes cash on hand, bank deposits, and short-term, highly liquid investments that are readily convertible to known amounts of cash. (Represents the company's immediate liquidity and ability to fund operations and short-term obligations.)

Total Stockholders' Equity

The residual interest in the assets of an entity after deducting all its liabilities. It represents the net worth of the company. (A shift from a deficit to a positive balance indicates successful capital raising and improved financial standing.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (Crucial for a biotech company like PLUS THERAPEUTICS, as it reflects investment in future growth and product pipeline.)

Lincoln Park Purchase Agreement

A financing agreement where a company can sell shares to an investor (Lincoln Park Capital Fund, L.P.) at prevailing market prices under certain conditions. (A significant source of capital for the company, but also a driver of share dilution.)

Common Shares Outstanding

The total number of shares of common stock that have been issued and are held by investors. (An increase indicates dilution, meaning each existing share represents a smaller percentage of ownership.)

Grant Revenue

Revenue generated from grants, typically from government agencies or foundations, often for research purposes. (A source of funding for the company's research activities, but can be less predictable than product sales.)

Year-Over-Year Comparison

Compared to the prior year, PLUS THERAPEUTICS has seen a significant widening of its net loss, increasing from $9.075 million in the first nine months of 2024 to $16.673 million in the same period of 2025. While operating expenses decreased due to lower R&D spending, grant revenue also declined. The most dramatic change is the substantial increase in cash reserves, driven by equity financing, which has also led to significant share dilution. Total stockholders' equity has moved from a deficit to a positive position, reflecting these capital raises.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 PSTV Nasdaq Capital Market Indica

Filing Documents

• pstv-20250930.htm (10-Q) — 2678KB
• pstv-ex10_2.htm (EX-10.2) — 183KB
• pstv-ex10_3.htm (EX-10.3) — 62KB
• pstv-ex31_1.htm (EX-31.1) — 15KB
• pstv-ex31_2.htm (EX-31.2) — 12KB
• pstv-ex32_1.htm (EX-32.1) — 18KB
• 0001193125-25-258596.txt ( ) — 10254KB
• pstv-20250930.xsd (EX-101.SCH) — 1328KB
• pstv-20250930_htm.xml (XML) — 1625KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39 Item 6. Exhibits 41 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") and the exhibits incorporated herein by reference contain "forward-looking statements" which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements other than statements of historical fact constitute "forward-looking statements." These forward-looking statements do not constitute guarantees of future performance. These forward-looking statements may be identified by terms such as "intend," "expect," "project," "believe," "anticipate," "initiate," "will," "should," "would," "could," "may," "designed," "potential," "evaluate," "hypothesize," "plan," "progressing," "proceeding," "exploring," "opportunity," "hopes," "suggest," and similar expressions, or the negative of such expressions. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about our anticipated expenditures, including research and development, and general and administrative expenses; our intent or ability to regain and maintain compliance with Nasdaq listing standards; our strategic collaborations and license agreements, intellectual property, U.S. Food and Drug Administration and European Medicines Agency approvals and interactions and government regulation; the potential size of the market for our product candidates; our research and development efforts; results from our preclinical and clinical studies and the implications of such results regarding the efficacy or saf

FINANC IAL INFORMATION

PART I. FINANC IAL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements PLUS THERAPEUTICS, INC. CONDEN SED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except share and par value data) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 13,289 $ 76 Investments 3,312 3,530 Grant receivable — 571 Other current assets 985 1,082 Total current assets 17,586 5,259 Property and equipment, net 273 448 Operating lease right-of-use assets 20 73 Goodwill 372 372 Intangible assets, net 374 469 Other assets 45 12 Total assets $ 18,670 $ 6,633 Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable and accrued expenses $ 11,623 $ 11,288 Operating lease liability 21 44 Deferred grant liability 1,972 927 Line of credit — 3,292 Total current liabilities 13,616 15,551 Noncurrent operating lease liability — 31 Total liabilities 13,616 15,582 Commitments and contingencies (Note 8) Stockholders' equity (deficit): Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.001 par value; 2,000,000,000 shares authorized; 131,863,969 shares issued; and 131,605,544 shares outstanding as of September 30, 2025, and 100,000,00 shares authorized; 6,154,758 shares issued; and 5,896,333 shares outstanding as of December 31, 2024, respectively 132 6 Treasury stock (at cost), 258,425 shares as of September 30, 2025 and December 31, 2024, respectively ( 500 ) ( 500 ) Additional paid-in capital 515,574 485,024 Accumulated deficit ( 510,152 ) ( 493,479 ) Total stockholders' equity (deficit) 5,054 ( 8,949 ) Total liabilities and stockholders' equity $ 18,670 $ 6,633 See Accompanying Notes to these Condensed Consolidated Financial Statements 4 Tab

View Full Filing

View this 10-Q filing on SEC EDGAR